Craig Washington, MD
General Practice · Frederick, MDNPI 1043731946
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $264,363 of the $270,886 with a category attached, or 97.6%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 98.6% of it on its own, with 29 other manufacturers making up the rest. Among general practice clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 343 payments — averaging $789.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$267K
- Novo Nordisk$643
- Lilly USA, LLC$405
- AbbVie$362
- Amgen$312
- Pfizer$298
- plus $2K from 24 others
What the payments were for
- Consulting fees$264,36398%
- Travel & lodging$2,5701%
- Food & beverage$3,9531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 155 | $267,072 |
| Novo Nordisk | 35 | $643 |
| Lilly USA, LLC | 24 | $405 |
| AbbVie | 16 | $362 |
| Amgen | 10 | $312 |
| Pfizer | 15 | $298 |
| Medtronic | 3 | $175 |
| AstraZeneca | 9 | $172 |
| Exact Sciences | 8 | $159 |
| Johnson & Johnson | 7 | $156 |
| Bayer | 7 | $145 |
| Novartis | 7 | $120 |
| Merck | 7 | $117 |
| Boehringer Ingelheim | 6 | $110 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $99 |
| GSK | 5 | $96 |
| Shield Therapeutics Inc | 4 | $77 |
| Corcept Therapeutics | 3 | $60 |
| Amarin Pharma, Inc. | 2 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Phadia US Inc. | 2 | $31 |
| Gilead | 1 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Astellas Pharma US Inc | 1 | $15 |
| Minerva Surgical, Inc | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$137
How this compares
$270,886 in reported general payments places this provider in the 95th percentile of 1,843 general practice providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 26 | $36,090 |
| EliquisApixaban | 28 | $26,498 |
| JanuviaSitagliptin Phosphate | 14 | $21,995 |
| TrulicityDulaglutide | 11 | $17,904 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $17,559 |
| FarxigaDapagliflozin Propanediol | 15 | $13,941 |
| MounjaroTirzepatide | 12 | $12,006 |
| DexilantDexlansoprazole | 11 | $3,258 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,930 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $2,492 |
| Atorvastatin Calcium | 149 | $1,337 |
| Rosuvastatin Calcium | 63 | $1,330 |
| Azelastine Hcl | 29 | $1,158 |
| Levetiracetam | 14 | $1,143 |
| Omeprazole | 57 | $1,117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $156 | $36,09026 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $405 | $29,91023 claims |
| PfizerEliquis | $298 | $26,49828 claims |
| MerckJanuvia | $117 | $21,99514 claims |
| GSKTrelegy Ellipta | $96 | $17,55913 claims |
| AstraZenecaFarxiga, Symbicort | $172 | $16,87127 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $267,072 | $3,25811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,843 general practice providers in Maryland.
Other general practice in Frederick
- Michael PesinFrederick$5K
- Nancy WardBaltimore$282K
- Paul NiesenGaithersburg$257K
- Kevin FriedmanBethesda$148K
- Edward SwansonBaltimore$123K
- Gregori KurtzmanSilver Spring$112K
- Russell MorrowWaldorf$86K
- Thomas YoonGaithersburg$73K
- Eric RabovskyCrownsville$35K
- Brittany BergeronTowson$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.